Experimental drug aims to halt rare heart disease
NCT ID NCT03702829
First seen Feb 20, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This study tested a drug called inotersen in 31 adults with TTR amyloid cardiomyopathy, a condition where abnormal protein builds up in the heart and causes progressive damage. The drug works by reducing the production of that protein in the liver. The goal was to see if it could slow or stop heart decline over 24 months, but the study was ended early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.